Compare ADMA Biologics Inc (ADMA) vs Warner Music Group Corp (WMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Warner Music Group Corp — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Warner Music Group Corp trades at $29.08 (market cap $14.83B). The key difference: Warner Music Group Corp is far larger — about 7× ADMA Biologics Inc's market cap, and Warner Music Group Corp pays a 2.67% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WMG | |
|---|---|---|
Market Cap | $2.13B | $14.83B |
Sector | Health | Media |
52-Week High | $20.38 | $34.72 |
52-Week Low | $7.60 | $23.65 |
Enterprise Value | $2.20B | $19.03B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Warner Music Group (WMG) trades at $28.44, up 0.57% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.35, beating expectations, and announced the acquisition of Sureel AI to strengthen IP management. Financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Valuation ratios include a P/E of 32.62 and P/S of 2.01, with a consensus analyst price target of $40.40 indicating significant upside potential.
WMG presents a mixed outlook: strong analyst support (66.7% buy ratings) and strategic AI investments offer growth opportunities, but bearish technicals, declining net margins, and competitive pressures pose risks. The stock's current price near support at $27 suggests cautious investor sentiment, with earnings consistency and margin improvement key to unlocking upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
